Pharmadrug Inc. (G11.F)
- Newsfile
PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs is pleased to provide a Corporate update from CEO, Robert Steen, to outline its forward strategic and tactical plan to move its patent pending novel manufacturing method for the commercial-scale manuf
- Newsfile
PharmaDrug Announces Director Appointment and Resignation
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board of directors, subject to approval of the Canadian Securities Exchange.Zalman Goldman is the founding
- Newsfile
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) owned by PharmaThe
